Clinical Trials on ALK Negative NSCLC

Total 434171 results

Tongji University

Recruiting

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLC

China
Arbeitsgemeinschaft medikamentoese Tumortherapie

Recruiting

Lung Cancer Registry

Lung Cancer | NSCLC Stage IV | NSCLC, Stage III | SCLC, Extensive Stage | SCLC, Limited Stage

Austria
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | TNBC - Triple-Negative Breast Cancer | NSCLC Stage IV Without EGFR/ALK Mutation

United States, Canada
Fujian Cancer Hospital

Enrolling by invitation

Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

EGFR/ ALK-negative Advanced NSCLC

China
Baodong Qin

Unknown

Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

NSCLC Stage IV | Anlotinib | EGFR T790M-negative | JS001

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring

Untreated Advanced NSCLC Patients | FISH Identified ALK Fusion Positive or Negative

China
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

NSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MF

China
Merck Sharp & Dohme LLC

Terminated

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Non-small Cell Lung Cancer (NSCLC) | Triple Negative Breast Cancer (TNBC) | NUT Midline Carcinoma (NMC) | Castration-resistant Prostate Cancer (CRPC)
Maastricht Radiation Oncology
Academisch Ziekenhuis Maastricht

Terminated

Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation (FDG-PET lung)

NSCLC | Lung Cancer | SCLC

Netherlands
Shanghai Henlius Biotech

Completed

Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects

NSCLC

China
The Netherlands Cancer Institute

Enrolling by invitation

The Food-effect on Alectinib Pharmacokinetics

NSCLC

Netherlands
Biocartis NV
AstraZeneca

Withdrawn

EGFR_IUO 3.20 Clinical Study Protocol

NSCLC
Centre Oscar Lambret
University Hospital, Lille

Terminated

Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation (CONCORDE)

Nsclc

France
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects

NSCLC

China
Bio-Thera Solutions

Completed

Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects

NSCLC

New Zealand
VelosBio Inc.

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Gastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditions

United States, Canada
Xinqiao Hospital of Chongqing

Completed

Clinical Research for the Consistency Analysis of PD-L1 in Cancer Tissue and Plasma Exosome (RadImm01)

NSCLC
Seoul St. Mary's Hospital
Boehringer Ingelheim

Active, not recruiting

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

NSCLC

Korea, Republic of
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Tri-Service... and other collaborators

Unknown

Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

NSCLC

Taiwan
AstraZeneca

Completed

Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study

NSCLC

Sweden, Bulgaria, Mexico, Russian Federation, Turkey, United Kingdom, Philippines, Malaysia, Germany, Hungary, Latvia, Lithuania, Poland, Romania, Netherlands, Norway, Argentina, Australia, Canada, Slovakia, Greece, Taiwan, Thailand, ... and more
Jiangsu Province Nanjing Brain Hospital

Recruiting

The Dynamic Monitoring of Cerebrospinal Fluid ctDNA

NSCLC

China
TYK Medicines, Inc

Recruiting

Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects

NSCLC

China
Radboud University Medical Center
Pfizer; ImaginAb, Inc.; University Hospital Tuebingen

Not yet recruiting

Immuno-pet iMaging resPonses administeRed Immune checkpoiNt inhibiTor (IMPRINT)

NSCLC

Germany, Netherlands
Beta Pharma, Inc.

Completed

A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711

NSCLC

China
Pfizer

Completed

A Rollover Protocol of Dacomitinib For Patients In Japan

NSCLC

Japan
Tianjin Medical University Cancer Institute and...
Guangzhou Burning Rock Dx Co., Ltd.; AstraZeneca Investment (China) Co., Ltd

Completed

Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing

NSCLC
Betta Pharmaceuticals Co., Ltd.

Unknown

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

ALK-POSITIVE NSCLC

China
Xiaorong Dong

Unknown

The Role of Microbiota on the Development of Lung Cancer

Healthy Subjects | NSCLC Stage IV | NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage II

China
Fox Chase Cancer Center
WindMIL Therapeutics

Withdrawn

Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab

NSCLC | SCLC
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Alectinib-induced Endocrine Toxicity (TOSS-ALK)

NSCLC Stage IV

Italy
Spanish Lung Cancer Group

Completed

T790M Mutation Testing in Blood by Different Methodologies

NSCLC Stage IV

Spain
ModernaTX, Inc.
AstraZeneca

Active, not recruiting

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma

United States, Israel, Australia
AbbVie

Active, not recruiting

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Cancer | Advanced Solid Tumors | Metastatic Solid Tumors | Triple-Negative Breast Cancer (TNBC) | Non-small-cell-lung-cancer (NSCLC)

United States, Australia, France, Israel, Spain, Taiwan
University Hospital Heidelberg
Roche Pharma AG

Recruiting

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (iReP)

NSCLC Stage IIIB | NSCLC Stage II | NSCLC, Stage IIIA

Germany
Jair Bar, M.D., Ph.D.

Not yet recruiting

Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib

Non-squamous NSCLC
The Netherlands Cancer Institute
AstraZeneca

Unknown

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment (Induction)

Stage III NSCLC

Netherlands
Shanghai Chest Hospital
The Affiliated Hospital of Qingdao University; Zhejiang University; Anhui Provincial...

Recruiting

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (AK104IIT018)

NSCLC Stage IV | NSCLC Stage IIIB | NSCLC Stage IIIC

China
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage II

China
Genentech, Inc.
Flatiron Health, Inc.; Foundation Medicine, Inc.

Completed

Prospective Clinicogenomic Program (PCG)

Non-Small Cell Lung Cancer (NSCLC) | Small-Cell Lung Cancer (SCLC)

United States
Fundación GECP

Active, not recruiting

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK)

NSCLC | Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB

Spain
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

United States, France, Taiwan, Canada, Italy, Singapore, Belgium, Spain, Israel
Peking Union Medical College

Recruiting

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB | NSCLC, Recurrent

China
Novartis Pharmaceuticals

Completed

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Melanoma | Triple Negative Breast Cancer | Anaplastic Thyroid Cancer | Other Solid Tumors | Non-small Sell Lung Cancer (NSCLC)

United States, Italy, Spain, Hungary, Taiwan, Germany, Netherlands, France, Norway, Poland, Thailand, Lebanon, Turkey, Canada
Jacobio Pharmaceuticals Co., Ltd.
AbbVie

Recruiting

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

NSCLC | Solid Tumor

United States
Biodesix, Inc.

Active, not recruiting

A Registry to Evaluate the Performance of the BDX-XL2 Test (ORACLE)

NSCLC | Nodule Solitary Pulmonary

United States
EQRx, Inc.

Completed

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

NSCLC | Healthy Volunteers | Pharmacokinetics

United States, New Zealand
Shanghai Chest Hospital

Unknown

SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations

NSCLC | SBRT | GM-CSF

China
Exelixis

Completed

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Cancer | NSCLC | Solid Tumors

Japan
Rain Oncology Inc

Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN)

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong

Clinical Trials on ALK Negative NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations